Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Rafael Holdings Inc (RFL)

Rafael Holdings Inc (RFL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL) Business Wire - Tue May 2, 2023

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation...

CYTH : 1.4700 (+1.38%)
RFL : 1.6000 (+0.63%)
Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D. Globe Newswire - Wed Jul 6, 2022

CRANBURY, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer...

RFL : 1.6000 (+0.63%)
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE Globe Newswire - Thu Jun 16, 2022

Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer...

RFL : 1.6000 (+0.63%)
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism Globe Newswire - Thu Jun 16, 2022

Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer...

RFL : 1.6000 (+0.63%)
Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results Globe Newswire - Tue Jun 14, 2022

NEWARK, N.J., June 14, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics...

RFL : 1.6000 (+0.63%)
Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Globe Newswire - Wed Jun 1, 2022

Cranbury, NJ, June 01, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer...

RFL : 1.6000 (+0.63%)
European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer Globe Newswire - Tue May 24, 2022

Cranbury, NJ, May 24, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer...

RFL : 1.6000 (+0.63%)
Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results Globe Newswire - Thu Mar 17, 2022

NEWARK, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics...

RFL : 1.6000 (+0.63%)
William “Bill” Conkling to assume the role of Chief Executive Officer as of February 1, 2022 Globe Newswire - Fri Jan 21, 2022

NEWARK, N.J., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), a company focused on discovering and developing novel cancer and...

RFL : 1.6000 (+0.63%)
Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer Globe Newswire - Tue Jan 18, 2022

CRANBURY, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the growing field of...

RFL : 1.6000 (+0.63%)

Barchart Exclusives

3 Dividend Kings That Cut (Or Will Cut) Their Dividends Barchart - Fri May 10, 6:00PM CDT
Dividend aristocracy isn't always a sure thing. Here are 3 companies that have been or will be booted from the coveted king's list. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot